- PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence
Arunaksharan Narayanankutty, 2019, Current Drug Targets CrossRef - Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment
Xianbo Wu et al, 2022, Frontiers in Pharmacology CrossRef - Genomic signature of MTOR could be an immunogenicity marker in human colorectal cancer
Chenxing Wang et al, 2022, BMC Cancer CrossRef - NVP-BEZ235 Inhibits Renal Cell Carcinoma by Targeting TAK1 and PI3K/Akt/mTOR Pathways
Bihui Li et al, 2022, Frontiers in Pharmacology CrossRef - Weighing In on mTOR Complex 2 Signaling: The Expanding Role in Cell Metabolism
Yongting Luo et al, 2018, Oxidative Medicine and Cellular Longevity CrossRef - Therapeutically actionable signaling node to rescue AURKA driven loss of primary cilia in VHL-deficient cells
Pratim Chowdhury et al, 2021, Scientific Reports CrossRef - Phytochemicals and Nanoparticles in the Modulation of PI3K/Akt/mTOR Kinases and its Implications in the Development and Progression of Gastrointestinal Cancers: A Review of Preclinical and Clinical Evidence
Arunaksharan Narayanankutty et al, 2023, Recent Patents on Anti-Cancer Drug Discovery CrossRef - Structural Aspects of mTOR Inhibitors: Search for Potential Compounds
Kamalpreet Kaur et al, 2022, Anti-Cancer Agents in Medicinal Chemistry CrossRef